Achieving a safe and early discharge for patients with community-acquired pneumonia (Q34423523)

2 August 2017

1 reference

title

Achieving a safe and early discharge for patients with community-acquired pneumonia (English)

1 reference

2 August 2017

Rhew DC

1

1 reference

PubMed ID

11686189

2 August 2017

Weingarten SR

series ordinal

2

1 reference

2 August 2017

1 November 2001

1 reference

Medical Clinics of North America

2 August 2017

1 reference

2 August 2017

85

1 reference

2 August 2017

1427-1440

1 reference

2 August 2017

6

1 reference

Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial.

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Is an observation period necessary after intravenous antibiotics are changed to oral administration?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Predicting the need for hospitalization of ambulatory patients with pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Intravenous-to-oral antibiotic switch therapy. A cost-effective approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Programs promoting timely sequential antimicrobial therapy: an American perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

The utility of an in-hospital observation period after discontinuing intravenous antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening patient stay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

A prediction rule to identify low-risk patients with community-acquired pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

The hospital discharge decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Economic impact of oral ciprofloxacin following standard intravenous therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Antibiotic optimization. An evaluation of patient safety and economic outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Antibiotic therapy in pneumonia: a comparative study of parenteral and oral administration of penicillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Retrospective analysis of risk factors and prognosis in non-ventilated patients with nosocomial pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Purpose of quality standards for infectious diseases. Infectious Diseases Society of America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Pharmacist-managed intravenous to oral step-down program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Prospective payment system and impairment at discharge. The 'quicker-and-sicker' story revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Symptoms in hospitalized patients: outcome and satisfaction with care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

The effect of intravenous-to-oral switch guidelines on the use of parenteral antimicrobials in medical wards

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Evaluation of the use of cefuroxime and cefuroxime axetil in an intravenous-oral stepdown program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Sequential antimicrobial therapy--the role of quinolones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Critical pathways as a strategy for improving care: problems and potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Switch therapy with beta-lactam/beta-lactamase inhibitors in patients with community-acquired pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Early Switch From Intravenous to Oral Antibiotics and Early Hospital Discharge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

A prospective, multicenter study of a pneumonia practice guideline.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Benchmark analysis of strategies hospitals use to control antimicrobial expenditures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Third generation cephalosporins in the parenteral to oral switch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Oral cephalosporins for use in a parenteral-to-oral switch programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Evaluation of a critical pathway for pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

On squeezing balloons. Cost control fails again

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

The epidemiology of delays in a teaching hospital. The development and use of a tool that detects unnecessary hospital days.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

A guide to the treatment of lower respiratory tract infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Evaluation of a pneumonia practice guideline in an interventional trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Identification of low-risk hospitalized patients with pneumonia. Implications for early conversion to oral antimicrobial therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Reducing costs and hospital stay for pneumonia with home intravenous cefotaxime treatment: results with a computerized ambulatory drug delivery system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

Development of an intravenous-to-oral route conversion program for antimicrobial therapy at a Canadian tertiary care health facility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970389-8

10.1016/S0025-7125(05)70389-8

7 January 2021

Identifiers

DOI

1 reference

release_fcrgazpzv5bfbgilkk5nrayrqq

2 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fcrgazpzv5bfbgilkk5nrayrqq

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

11686189

1 reference

PubMed ID

11686189